Growth Stock Analytics-High EPS and Relative Strength Stock Market Trading System Growth Stock Analytics-High EPS and Relative Strength Stock Market Trading System
Growth Stock Investing and Trading for Stock Market Investors - Since 1996 | MyStockScreen.com | Home | Join Now | Member Login | Refer a Friend | Contact Us
Your Best Source For Top Stock Picks, Stock Rankings, Stock Screening, Swing Trading, Market Direction and More...
HI-EPSRS
Screener
My Watch
List
Market
Direction
Industry
Map
My
Account
Help Logout
Symbol:
Enter Symbols Separated By Spaces.
Download All Symbols To Text/CSV

Top Picks Watch List
Dist.Days: SPY:4 DOW:4 QQQ:2

GSA Live Portfolio:
FNSR PRO
2022-11-08: We have a signal to move out of CASH and into FBSOX....Read more

HI-EPSRS Database Search Results   

Search Results      Stocks 1 through 1 of 1 shown        Download Search Results Symbols To Text/CSV

ResMed Inc (RMD)
Vital Signs
GSA
Rank

Stock Ranking
Earnings
Consistency

EPS Consistency Ranking

0.0/1.0
Sales
Consistency

Sales Consistency Ranking

0.7/1.0
Looks Like
A Winner?

Looks Like A Winner Ranking

3/10
Entry Risk
Above Support

Price Above Stop Loss Ranking

2%
Group
Action

Group Action Ranking

15
"Must Have"/Timing Factors
GSA
60.58
Acc Dist
1.61
Disc
89.47%
Avg Vol
570,100
Liquidity
0.45%
Below High
3.07%
Group Action
15
3-Month Trends of Key Indicators:
Fundamental/Technical Factors
Qrtly EPS
11%  20%
EPS Growth
-2%
Sls Growth
8%
Proj Growth
15%
Anal. Rank
2.33
Shares
142M
Instit
64%
3-Month Trends of Key Indicators:
Looks Like a Winner?
RMD looks better than most Top Picks Winners* in 3 out of 10 key factors.
Accum/Dist: 1.61 (median winner: 1.53)
Above 40wkMA: 14% (median winner: 35%)
Instit. Ownership: 64% (median winner: 63%)
Liquidity: 0.45% (median winner: 1.18%)
Group Action: 15 (median winner: 20)
GSA Rank: 60.58 (winner: 75.66)
Sales Growth: 8% (median winner: 28%)
Below 52wk High: 3.07% (winner: 3.30%)
Relative Strength: 84 (winner: 96)
Avg Qrtly EPS: 16% (median winner: 68%)
Industry Group: 15. Medical Appliances & Equipment

Instit.   Insiders   Yahoo   Zacks   MSN   Google Finance   Daily Charts   Web Site

  • See what the IHS Markit Score report has to say about ResMed Inc. Mon, 20 Nov 2017 13:08:07 +0000
    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 31. Index (PMI) data, output in the Healthcare sector is rising.
  • 3 Top Medical Device Stocks to Buy Now Sat, 18 Nov 2017 16:32:00 +0000
    Looking to put money to work in this under-the-radar sector? Here are three top stocks to consider.
  • ResMed Elects Karen Drexler to Its Board of Directors Fri, 17 Nov 2017 14:00:00 +0000
    ResMed Elects Karen Drexler to Its Board of Directors
  • ETFs with exposure to ResMed, Inc. : November 13, 2017 Mon, 13 Nov 2017 18:07:13 +0000
    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ResMed, Inc. Here are 5 ETFs with the largest exposure to RMD-US. Comparing the performance and risk of ResMed, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
  • Statement by ResMed on United Kingdom Case with Fisher & Paykel Mon, 13 Nov 2017 01:51:00 +0000
    SAN DIEGO , Nov. 13, 2017 /PRNewswire/ -- ResMed (NYSE: RMD, ASX: RMD) today issued the following statement from David Pendarvis , the company's global general counsel and chief administrative officer: ...
  • Fisher & Paykel says UK court rules rival Resmed's patent is invalid Sun, 12 Nov 2017 22:16:16 +0000
    New Zealand's Fisher & Paykel Healthcare (FPH.NZ) said on Monday that it could continue to sell its sleep apnea masks in Britain as a UK court had ruled that rival Resmed Inc's (RMD.N) patent was invalid. Fisher & Paykel filed the case against California-based Resmed in Britain's High Court in 2016, and has similar legal proceedings underway in Germany, after Resmed had said the New Zealand company's masks violated Resmed patents. "This result confirms that UK patients can continue to purchase and enjoy the benefits of our high-performance masks," Fisher & Paykel said in a statement in which it announced the UK court ruling.
  • Lifshitz & Miller LLP Announces Investigation of Calpine Corporation, Deltic Timber Corporation, FactSet Research Systems Inc., Intel Corporation, Norwegian Cruise Line Holdings Ltd., ResMed Inc. and Tyler Technologies, Inc. Sat, 11 Nov 2017 00:01:00 +0000
    NEW YORK , Nov. 10, 2017 /PRNewswire/ -- Calpine Corporation (CPN) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale ...
  • SleepScore Labs Launches the World's Most Advanced Sleep Improvement System Fri, 10 Nov 2017 14:00:00 +0000
    CARLSBAD, Calif., Nov. 10, 2017 /PRNewswire/ -- SleepScore Labs, the company behind the most advanced non-contact sleep improvement systems for consumers, announced today the availability of its newest non-contact device, SleepScore Max. SleepScore Max, available for purchase at www.sleepscore.com, is the world's most accurate and sophisticated sleep improvement system. Small and attractive enough to sit on a nightstand, the device calculates a nightly SleepScore (between 0–100) based on an individual's quality and quantity of sleep – without the need for a wearable tracker or bed strip beneath the mattress.
  • Read This Before Buying ResMed Inc (RMD) For Its Upcoming $0.35 Dividend Sat, 04 Nov 2017 00:49:27 +0000
    Important news for shareholders and potential investors in ResMed Inc (NYSE:RMD): The dividend payment of $0.35 per share will be distributed into shareholder on 14 December 2017, and the stockRead More...
  • ResMed, Inc. :RMD-US: Earnings Analysis: Q1, 2018 By the Numbers : November 1, 2017 Wed, 01 Nov 2017 13:34:16 +0000
    Categories: Yahoo FinanceGet free summary analysis ResMed, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ResMed, Inc. – Thermo Fisher Scientific Inc. (TMO-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 523.66 million, Net Earnings of USD 86.13 million. ... Read more (Read more...)

Stock Research
Weekly-1Yr Daily-3Mo Daily-6Mo Daily-1Yr
Daily-6Mo w/2-ATR Stops 3-ATR 4-ATR
Daily-1 Yr (opens in new window)
(Larger Charts. ATR=Average True Range)

Stock Research
Rel Str Acc/Dist Grp Action Instit Disc%

Quarterly EPS GrowthQuarterly Sales Growth
RMD EPS/Sales Growth RMD vs. Peers



*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.
Copyright © 1996-2024 Growth Stock Analytics, LLC. All rights reserved.  Site Map | Privacy Policy | Contact Us